{
    "2025-01-13": [
        {
            "title": "J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders",
            "description": "Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday that it will pay $132 in cash for each share of Intra-Cellular…",
            "source": "Financial Post",
            "url": "https://financialpost.com/pmn/jj-buys-intra-cellular-in-14-6-billion-deal-delving-further-into-central-nervous-system-disorders",
            "publishedAt": "2025-01-13T15:33:09Z"
        }
    ],
    "2025-01-27": [
        {
            "title": "J&J-Backed Medtech Firm HistoSonics Considers US IPO",
            "description": "HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US initial public offering as soon as this year, according to people familiar with the matter.",
            "source": "Financial Post",
            "url": "https://financialpost.com/pmn/business-pmn/jj-backed-medtech-firm-histosonics-considers-us-ipo",
            "publishedAt": "2025-01-27T20:14:14Z"
        }
    ]
}